Oral anticoagulation thresholds

Circulation

Volumn 104, Issue 19, 2001, Pages 2311-2317

  Brummel, Kathleen E ^a   Paradis, Sara G ^a   Branda, Richard F ^b   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Anticoagulants; Coagulation; Hemorrhage; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8; FIBRINOPEPTIDE A; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL STANDARD UNIT; MALE; NORMAL HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 0035818511     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4401.098492     Document Type: Article

References (28)

1. Vitamin K epoxide and quinone reductase activities: Evidence for reduction by a common enzyme
2. Vitamin K and the biosynthesis of prothrombin, IV: Isolation of peptides containing prosthetic groups from normal prothrombin and the corresponding peptides from dicoumarol-induced prothrombin
3. The mode of action of vitamin K: Identification of gamma-carboxyglutamic acid as a component of prothrombin
4. Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors
5. Tissue factor and hemostasis
6. Oral anticoagulant drugs: Pharmacokinetic aspects
7. Vitamin K and the oral anticoagulant drugs
8. The effectiveness of an oral vitamin K in controlling excessive hypothrombinemia during anticoagulant therapy
9. Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: Outpatient management for adults
10. Analysis and occurrence of adverse events with oral anticoagulant therapy
11. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
12. Consensus guidelines for warfarin therapy: Recommendations from the Australasian Society of Thrombosis and Haemostasis
13. Blood clotting in minimally altered whole blood
14. Blood coagulation in hemophilia A and hemophilia C
15. An integrated study of fibrinogen during blood coagulation
16. A simple method for the preparation of homogeneous phospholipid vesicles
17. Extrinsic pathway proteolytic activity
18. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
19. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
20. Human platelet osteonectin: Release, surface expression, and partial characterization
21. The prothrombin time in haemophilia and in obstructive jaundice
22. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, factor XIII and by enhancing factor Va inactivation
23. Antiplatelet agents in tissue factor-induced blood coagulation
24. The effect of thrombocytopenia on the tissue factor pathway
25. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy
26. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors
27. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
28. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phaseresponse